Skip to content
Skip to site navigation
Skip to local navigation
Search
Search
Department of Health and Aged Care
Medical Services Advisory Committee
Search
Search
MSAC
About MSAC
About MSAC
MSAC Terms of Reference
MSAC Membership
MSAC Executive Terms of Reference
ESC Terms of Reference
ESC Membership
PASC Terms of Reference
PASC Membership
MSAC Meetings
PASC, ESC, MSAC Key Dates
Codependent Technologies
Meeting Agendas
MSAC Processes
How to Apply for Public Funding
MSAC Process Framework
Frequently Asked Questions
Fact Sheets
Forms Templates
& Guidelines
MSAC Guidelines
Documents for Applicants and Assessment Groups
Additional Resources
Engaging with MSAC
Information for Applicants
MSAC Consultation Process
MSAC Applications
Application Page
Utilisation Monitoring
Process
You are here:
Medical Services Advisory Committee
/
MSAC Meetings
/
Meeting Agendas
/
MSAC - Meeting 22-23 November 2018
Page last updated: 11 January 2019
Medical Services Advisory Committee - Applications Considered
1357.1 - F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer
1405.1 - MBS Item Number for Pulmonary Rehabilitation
1407 - EGFR mutation testing to determine eligibility for access to PBS subsidised osimertinib second line therapy in patients with locally advanced or metastatic NSCLC
1455 - Proton Beam Therapy for patients supported under the Medical Treatment Overseas Program
1456 - 17p Deletion Testing for Access to Venetoclax in Patients with Relapsed/Refractory Chronic Lymphoid Leukaemia
1466 - Vertebroplasty for severely painful osteoporotic vertebral fractures of less than 6 weeks duration
1498 - Serum Soluble Transferrin receptor
1510 - Emicizumab for routine prophylaxis, to prevent bleeding or reduce frequency of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency), with factor VIII inhibitors
1519 - Tisagenlecleucel (CTL019 - CAR-T therapy) for treatment of refractory CD19-positive leukaemia and lymphoma
1530 - Purified human alpha1-proteinase inhibitor (A1-P1) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)
1541 - Micro-bypass glaucoma surgery (MBGS) device implantation as a standalone procedure in patients with open-angle glaucoma
1543 - Request to amend Medicare Benefits Schedule (MBS) item 73336 (BRAF mutation test for treatment of metastatic melanoma) to include reference to encorafenib
Listen
MSAC Meetings
PASC, ESC, MSAC Key Dates
Codependent Technologies
Meeting Agendas
MSAC Email Bulletin
Email: